1432055-38-3Relevant academic research and scientific papers
Cholesteryl ester transfer protein (CETP) inhibitors based on cyclic urea, bicyclic urea and bicyclic sulfamide cores
Liu, Jian,Shao, Patrick P.,Guiadeen, Deodial,Krikorian, Arto,Sun, Wanying,Deng, Qiaolin,Cumiskey, Anne-Marie,Duffy, Ruth A.,Murphy, Beth A.,Mitra, Kaushik,Johns, Douglas G.,Duffy, Joseph L.,Vachal, Petr
, (2021)
Cholesteryl ester transfer protein (CETP) inhibitors reduce the transfer of cholesteryl esters from the high-density lipoprotein (HDL-C) to apolipoprotein such as VLDL/LDL, with exchange of triglycerides. Thus, this inhibition increases the HDL-C levels, which is believed to lower the risk for heart disease and stroke. We report here a series of CETP inhibitors based on the cyclic, bicyclic urea and sulfamide cores. These CETP inhibitors exemplified by 15, 31, and 45 demonstrated in vitro potency in inhibiting the CETP transfer activity, and 15, 31 showing in vivo efficacy to increase HDL-C levels in cynomolgus-CETP transgenic mice. The synthesis and biological evaluations of these CETP inhibitors are described.
Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties ()
Vachal, Petr,Duffy, Joseph L.,Campeau, Louis-Charles,Amin, Rupesh P.,Mitra, Kaushik,Murphy, Beth Ann,Shao, Pengcheng P.,Sinclair, Peter J.,Ye, Feng,Katipally, Revathi,Lu, Zhijian,Ondeyka, Debra,Chen, Yi-Heng,Zhao, Kake,Sun, Wanying,Tyagarajan, Sriram,Bao, Jianming,Wang, Sheng-Ping,Cote, Josee,Lipardi, Concetta,Metzger, Daniel,Leung, Dennis,Hartmann, Georgy,Wollenberg, Gordon K.,Liu, Jian,Tan, Lushi,Xu, Yingju,Chen, Qinghao,Liu, Guiquan,Blaustein, Robert O.,Johns, Douglas G.
supporting information, p. 13215 - 13258 (2021/09/02)
Cholesteryl ester transfer protein (CETP) represents one of the key regulators of the homeostasis of lipid particles, including high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles. Epidemiological evidence correlates increased HDL and decreased LDL to coronary heart disease (CHD) risk reduction. This relationship is consistent with a clinical outcomes trial of a CETP inhibitor (anacetrapib) combined with standard of care (statin), which led to a 9% additional risk reduction compared to standard of care alone. We discuss here the discovery of MK-8262, a CETP inhibitor with the potential for being the best-in-class molecule. Novel in vitro and in vivo paradigms were integrated to drug discovery to guide optimization informed by a critical understanding of key clinical adverse effect profiles. We present preclinical and clinical evidence of MK-8262 safety and efficacy by means of HDL increase and LDL reduction as biomarkers for reduced CHD risk.
BICYCLIC UREAS AND THIADIAZOLIDINE-1,1-DIOXIDES AS CETP INHIBITORS
-
Page/Page column 40; 41, (2015/02/25)
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is -C(=O) or -S(O)2-, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
SPIROCYCLIC CETP INHIBITORS
-
Page/Page column 38; 39, (2014/07/08)
Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing at
FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR
-
Paragraph 0280; 0281, (2013/05/09)
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
LONG INTERFERING DSRNA SIMULTANEOUSLY INDUCING AN IMMUNE REACTION AND THE INHIBITION OF THE EXPRESSION OF TARGET GENES
-
Page/Page column 40; 41; 42, (2013/11/19)
The present invention relates to a long interfering dsRNA (liRNA) capable of promoting an immune reaction as well as inhibiting the expression of specific RNAi-mediated target genes, and to uses thereof. More particularly, the present invention relates to
